Factor concentrate usage in persons with hemophilia in New York state

Transfusion

Volumn 43, Issue 4, 2003, Pages 470-475

  Linden, Jeanne V ^a   Kolakoski, Marcia H ^b   Lima, Jennifer E ^b   Du, Ping ^b   Lipton, Richard A ^b  

^a WADSWORTH CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 9 CONCENTRATE;

ADOLESCENT; ADULT; ARTICLE; BLEEDING; CHILD; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; HEMOPHILIA A; HEMOPHILIA B; HUMAN; IMMUNOLOGICAL TOLERANCE; INFANT; MAJOR CLINICAL STUDY; NEWBORN; PATIENT CARE; PROPHYLAXIS; TREATMENT OUTCOME; TREATMENT PLANNING;

FACTOR IX; FACTOR VIII; HEMOPHILIA A; HEMORRHAGE; HUMANS; NEW YORK; RECOMBINANT PROTEINS;

EID: 0037388669     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1537-2995.2003.00343.x     Document Type: Article

References (24)

1. Soucie JM, Evatt B, Jackson D. Occurrence of hemophilia in the United States. The Hemophilia Surveillance System Project Investigators. Am J Hematol 1998;59:288-94.
2. Ahlberg A. Haemophilia in Sweden. VII. Incidence, treatment and prophylaxis of arthropathy and other musculoskeletal manifestations of haemophilia A and B. Acta Orthopaed Scand 1965;77(Suppl):3-132.
3. Nilsson IM, Berntorp E, Lofqvist T, Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Int Med 1992;232:25-32.
4. Aledort LM, Haschmeyer RH, Pettersson H. A longitudinal study of orthopaedic outcomes for severe factor VIII deficient haemophiliacs. The Orthopaedic Outcome Study Group. J Int Med 1994;236:391-9.
5. Ljung R, Aronis-Vournas S, Kurnik-Auberger K, et al. Treatment of children with haemophilia in Europe: a survey of 20 centres in 16 countries. Haemophilia 2000;6: 619-24.
6. Liesner RJ, Khair K, Hann IM. The impact of prophylactic treatment on children with severe haemophilia. Br J Haematol 1996;92:973-8.
7. Astermark J, Petrini P, Tengborn L, et al. Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized. Br J Haematol 1999;105:1109-13.
8. Manco-Johnson MJ, Nuss R, Funk S, Murphy J. Joint evaluation instruments for children and adults with haemophilia. Haemophilia 2000;6:649-57.
9. Antonarakis SE, Rossiter JP, Young M, et al. Factor VIII gene inversions in severe haemophilia A: results of an international consortium study. Blood 1995;86:2206-12.
10. Schwaab R, Brackmann HH, Meyer C, et al. Haemophilia A: mutation type determines risk of inhibitor formation. Thromb Haemost 1995;74:1402-6.
11. Katz J. Prevalence of factor IX inhibitors among patients with haemophilia B: results of a large scale North American survey. Haemophilia 1996;2:28-31.
12. Scharrer I, Bray GL, Neutzling O. Incidence of inhibitors in haemophilia A patients - a review of recent studies of recombinant and plasma-derived factor VIII concentrates. Haemophilia 1999;5:145-54.
13. Nilsson IM, Jonsson S, Sundquist S, et al. A procedure for removing high titer antibodies by extracorporeal proteinA-Sepharose adsorption in hemophilia: substitution therapy and surgery in a patient with hemophilia B and antibodies. Blood 1981;58:38-44.
14. Nilsson IM, Berntorp E, Zettervall O. Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide and factor VIII. N Engl J Med 1988;318:947-50.
15. DiMichele DM. Immune tolerance: a synopsis of the international experience. Haemophilia 1998;4:568-73.
16. Mariani G, Ghirardini A, Bellocco R. Immune tolerance in hemophilia - principal results from the international registry. Report of the Factor VIII and IX Subcommittee. Thromb Haemost 1994;72:155-8.
17. DiMichele DM, Kroner BL. Analysis of the North American Immune Tolerance Registry (NAITR) 1993-1997: current practice implications. ISTH Factor VIII/IX Subcommittee Members. Vox Sang 1999;77(Suppl 1):31-2.
18. Brackmann HH. Induced immunotolerance in factor VIII inhibitor patients. Prog Clin Biol Res 1984;150:181-95.
19. Negrier C, Goudemand J, Sultan Y, et al. Multicenter retrospective study on utilization of FEIBA in France in patients with factor VIII and IX inhibitors. French FEIBA Study Group. Factor VIII Bypassing Activity. Thromb Haemost 1997;77:1113-9.
20. Brettler DB, Forsberg AD, Levine PH, et al. The use of porcine factor VIII concentrate (Hyate: C) in the treatment of patients with inhibitor antibodies to factor VIII. A multicenter US experience. Arch Intern Med 1989;149:1381-5.
21. Lozier JN, Santagostino E, Kasper CK, et al. Use of porcine factor VIII for surgical procedures in hemophilia A patients with inhibitors. Semin Hematol 1993;2(Suppl 1):10-21.
22. Ingerslev J, Freidman D, Gastineau D, et al. Major surgery in haemophilic patients with inhibitors using recombinant factor VIIa. Haemostasis 1996;26(Suppl 1):118-23.
23. Schulman S. Safety, efficacy and lessons from continuous infusion with rFVIIa. rFVIIa-CI Group. Haemophilia 1998;4:564-7.
24. Soucie JM, Nuss R, Evatt B, et al. Mortality among males with hemophilia: relations with source of medical care. The Hemophilia Surveillance System Project Investigators. Blood 2000;96:437-42.